Orsini Chosen by Ascendis to Distribute Treatment for Rare Endocrine Disorder in the U.S.
Orsini Chosen by Ascendis to Distribute Treatment for Rare Endocrine Disorder in the U.S.
YORVIPATH is designed to provide continuous exposure to released PTH over the 24-hour dosing period. It is currently approved in the European Union, U.K. and European Economic Area.ELK GROVE VILLAGE, Ill., Dec. 9, 2024 /PRNewswire/ -- Orsini has been selected by Ascendis Pharma as a specialty pharmacy partner for YORVIPATH (palopegteriparatide), an FDA-approved parathyroid hormone analog (PTH(1-34)) indicated for the treatment of hypoparathyroidism in adults. Read the US Full Prescribing Information here.
伊利诺伊州埃尔克格罗夫村，2024年12月9日 /PRNewswire/ -- Orsini被Ascendis Pharma选为YORVIPATH（palopegteriparatide）的专业药房合作伙伴，该药物是经FDA批准的甲状旁腺激素类药物（PTH(1-34)），用于治疗成人低甲状旁腺功能亢进症。详细的美国处方信息请点击此处。
Chronic hypoparathyroidism is a rare disorder that affects about 70,000 people in the U.S., caused when a patient's body produces abnormally low levels of parathyroid hormone. This leads to low calcium levels and high phosphorus levels in the blood, and those living with chronic hypoparathyroidism can experience a range of symptoms including chronic pain, muscle cramps, cataracts, bone damage and kidney stones.
慢性低甲状旁腺功能亢进症是一种罕见疾病，影响美国约70,000人，患者体内甲状旁腺激素产生异常低，导致血钙水平低和血磷水平高，慢性低甲状旁腺功能亢进症患者可以经历一系列症状，包括慢性疼痛、肌肉痉挛、白内障、骨损伤和肾结石。
"We're thrilled to add YORVIPATH to our growing portfolio of endocrinology therapies."
"我们很高兴将YORVIPATH添加到我们不断增长的内分泌治疗组合中。"
YORVIPATH is designed to provide continuous exposure to released PTH over the 24-hour dosing period. It is currently approved in the European Union, U.K. and European Economic Area.
YORVIPATH旨在在24小时的给药期内提供持续的PTH暴露。该药物目前已在欧盟、英国和欧洲经济区获得批准。
"We're thrilled to add YORVIPATH to our growing portfolio of endocrinology therapies," Darin DeCarlo, Orsini's Chief Growth Officer, said. "Orsini is built to serve rare disease patients, and we're excited to partner with Ascendis to deliver this new treatment option to patients suffering from chronic hypoparathyroidism."
"我们很高兴将YORVIPATH添加到我们不断增长的内分泌治疗组合中，"Orsini的首席增长官Darin DeCarlo说。"Orsini致力于服务罕见疾病患者，我们很高兴与Ascendis合作，为慢性低甲状旁腺功能亢进症患者提供这种新治疗选择。"
About Orsini
关于奥尔西尼
Providing compassionate care since 1987, Orsini is a leader in rare disease and gene therapy pharmacy solutions, built to simplify how patients connect to advanced medicines. Through our comprehensive commercialization solutions including a nationwide specialty pharmacy, patient services hub, home infusion and nursing network, and third-party logistics provider, we work with biopharma, providers, and payors to ensure No Patient is Left Behind.
自1987年以来提供富有同情心的护理，Orsini在罕见疾病和基因治疗药品解决方案方面处于领先地位，旨在简化患者与爱文思控股的联系。通过我们的全面商业化解决方案，包括全国范围的专业药房、患者服务中心、家庭输注和护理网络以及第三方物流提供商，我们与生物制药公司、提供者和支付方合作，确保没有患者被落下。
Orsini holds accreditations with the Accreditation Commission for Health Care (ACHC), The Joint Commission, URAC and NABP. Orsini has earned URAC's Rare Disease Pharmacy Center of Excellence Designation and ACHC's Distinction in Rare Diseases and Orphan Drugs. For more information, contact Orsini at 847-734-7373 ext. 505, email us at [email protected], or visit .
Orsini获得了医疗保健认可委员会（ACHC）、the joint委员会、URAC和NABP的认证。Orsini获得了URAC的稀有疾病药房卓越中心认证和ACHC的稀有疾病与孤儿药物的特别荣誉。如需更多信息，请联系Orsini，电话847-734-7373，分机505，或发送电子邮件至[email protected]，或者访问。
SOURCE Orsini
来源：Orsini
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新闻在PRNEWSWIRE.COM上特色呈现吗？
